AI English summary of an SEC filing — figures as filed
Edwards Lifesciences EWThe company said TAVR sales for Q2 rose 5% to $1.0 billion (6% on a constant currency basis). It also lowered its full-year TAVR sales growth outlook to 5 to 7% from the prior 8 to 10%.
Key points
AI summaryThe company said TAVR sales for Q2 rose 5% to $1.0 billion (6% on a constant currency basis). It also lowered its full-year TAVR sales growth outlook to 5 to 7% from the prior 8 to 10%.
Edwards said TMTT sales for Q2 rose 75% to $83 million. The company also said it is raising its full-year TMTT sales outlook to the higher end of the prior $320 to $340 million range.
The company said diluted earnings per share for Q2 were $0.61 and adjusted (non-GAAP) EPS was $0.70. It said adjusted EPS was boosted by $0.04 from a lower-than-expected adjusted tax rate of 8.4%.
The company said it expects to pay approximately $1.2 billion in cash upfront at closing of its acquisitions of JenaValve and Endotronix, plus up to an additional $445 million upon achievement of certain milestones. Each acquisition is subject to the satisfaction or waiver of certain closing conditions.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Edwards Q2 TAVR sales of $1.0 billion and cut full-year TAVR outlook
The company said TAVR sales for Q2 rose 5% to $1.0 billion (6% on a constant currency basis). It also lowered its full-year TAVR sales growth outlook to 5 to 7% from the prior 8 to 10%.
Source · Based on the filing body and exhibits
TMTT sales of $83 million in Q2, full-year outlook raised to top of range
Edwards said TMTT sales for Q2 rose 75% to $83 million. The company also said it is raising its full-year TMTT sales outlook to the higher end of the prior $320 to $340 million range.
Source · Based on the filing body and exhibits
Q2 EPS $0.61, adjusted EPS $0.70
The company said diluted earnings per share for Q2 were $0.61 and adjusted (non-GAAP) EPS was $0.70. It said adjusted EPS was boosted by $0.04 from a lower-than-expected adjusted tax rate of 8.4%.
Source · Based on the filing body and exhibits
JenaValve and Endotronix acquisition consideration
The company said it expects to pay approximately $1.2 billion in cash upfront at closing of its acquisitions of JenaValve and Endotronix, plus up to an additional $445 million upon achievement of certain milestones. Each acquisition is subject to the satisfaction or waiver of certain closing conditions.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…